Navigation Links
USHIFU, LLC Completes Acquisition of Focus Surgery, Inc.
Date:7/2/2008

Combination Creates New Opportunities for Expansion of HIFU Technology

CHARLOTTE, N.C., July 2 /PRNewswire/ -- USHIFU, LLC (USHIFU), the distributor and provider of non-invasive high intensity focused ultrasound for prostate cancer, announced today that it has completed the acquisition of Focus Surgery, Inc. (FSI) of Indianapolis, IN, the creator and manufacturer of the Sonablate(R) 500, an image-guided acoustic ablation device. This acquisition will accelerate USHIFU's ability to expand the FSI HIFU technology platform, as well as gain access to new markets, such as India.

"I speak for the combined USHIFU and Focus Surgery team when I say we are thrilled to announce the acquisition of Focus Surgery. Watching the technological innovation that Focus Surgery scientists and engineers have consistently achieved over the last several years with limited resources has been nothing short of amazing," said Steve Puckett, Jr., CEO USHIFU. "As a much stronger combined entity we are more encouraged than ever about our ability to positively affect healthcare delivery around the world."

"A great milestone in the history of Focus Surgery, Inc. is achieved today as it combines all its technological strength with USHIFU, LLC. The combined Company will make HIFU rapidly available in approved markets worldwide for the treatment of a most deadly disease - cancer, which is very important," said Narendra Sanghvi, President, FSI. "In addition, this is also an extraordinary opportunity to quickly commercialize many of the advanced HIFU applications to create a medical revolution with bloodless surgery while maintaining high quality of life."

About USHIFU, LLC

USHIFU is a healthcare development company and medical device distributor committed to creating a new standard for prostate cancer treatment with high intensity focused ultrasound (HIFU) therapy. USHIFU works with hospitals and medical centers in countries where HIFU is authorized for treating
'/>"/>

SOURCE USHIFU, LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Southern Home Medical Equipment Completes 1-for-1,000 Reverse Split and Begins Trading Under New Symbol SHOM
2. KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission
3. Beeston completes drilling on Bluff Lake property, 100 Mile House
4. PreMD Successfully Completes Project for Health & Beauty Company
5. Sinexus Welcomes New CEO and Completes Series B
6. ACTS Retirement-Life Communities Completes Carlton Cove Acquisition
7. Health Fitness Completes Share Repurchase Plan
8. Lockheed Martin Completes Acquisition of Eagle Group International, LLC
9. The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009
10. Mindray Medical Completes Acquisition of Datascopes Patient Monitoring Business
11. Takeda Completes Acquisition of Millennium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...lleviates Insurance Claim Processing and Payment C...NTA, Dec. 2 SunTrust Ban...thcare receivables solution for medical and dental...Trust eClaim Revenue Gateway helps providers accel...nt collection and processing so that they can focu...
(Date:12/2/2008)...-- MicroPhage, Inc., http://www.microphage.com ,...ed,the company,s Board of Directors. Taussig was... Research Center in Denver, the nation,s leading i...m 1993 to 2006. His medical specialty,is pediatr...ge extensively and am impressed with its progress,...
(Date:12/2/2008)...to Connect - , , - Only 1 in 4 Teens Report...ngers - , , NEW YORK, Dec. 2 /PRNewswire/ ...ree America and MetLife Foundation shows that many...o communicate with their teens may be missing impo...ut drug and alcohol use. The national survey of mo...
(Date:12/2/2008)...RNewswire-USNewswire/ -- Fatigued medical resident...vision of work hour limits to improve patient safe...w Institute of Medicine report funded by HHS, Agen... The report is the result of a 15-month study by ...tween residents, work schedules, their performance...
Breaking Medicine News(10 mins):Health News:Healthcare Providers Now Able to Perform Real-Time Patient Eligibility Verification 2Health News:Healthcare Providers Now Able to Perform Real-Time Patient Eligibility Verification 3Health News:Healthcare Providers Now Able to Perform Real-Time Patient Eligibility Verification 4Health News:MicroPhage Selects Lynn Taussig, MD for Board of Directors 2Health News:Bridging the Technology Gap: Study Confirms Teens Open to Discussing Drugs and Alcohol With Parents By Email, Cell Phones 2Health News:Bridging the Technology Gap: Study Confirms Teens Open to Discussing Drugs and Alcohol With Parents By Email, Cell Phones 3Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 2Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 3Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 4
...he 10-year international Human Genome Project (HGP...o carry the highest concentration of disease genes...ved to be associated with genetic disease. Over t...ellcome Trust's Sanger Centre, near Cambridge, eas...
...tances we see couples who are HIV sero discordant ...is HIV –1 positive and the wife is negative and th... because sexual intercourse carries a 1 in 500 ris...the female partner and through her to the fetus. ...
...ss what they dream about? Their own rat races! Rea...d by scientists at the Massachusetts Institute of ...ng about rat races and that they might in the long...understand how the human mind works. Most pet...
...ts, doctors in Ohio, the United States of America,...to rid him of a painful ulcer due to a weakened va...time a bovine vein is used in man to treat varicos... Toledo hospital's Jobst Vascular Center at Toledo...
Other Medicine News:Health News:Sperm washing helps couples 2
(Date:12/2/2008)...PRNewswire/ -- Horizon Therapeutics, Inc., a,priv...ced that two pivotal,Phase 3 trials evaluating it...,met all primary endpoints. HZT-501, a novel, pro...g ibuprofen and famotidine, demonstrated a,statis...non-steroidal,anti-inflammatory drug (NSAID)-indu...
(Date:12/1/2008)...AGO, Dec. 2 A study has... new technique for imaging the breast, is not affe...l status, two factors that limit the effectiveness...er. Results will be presented today at the annual ...ca (RSNA). , , "The ability of PEM to dete...
(Date:12/1/2008)...ewswire/ -- S*BIO Pte Ltd today announced the init...potent and orally-active JAK2 inhibitor, in leadin...hronic idiopathic myelofibrosis (CIMF). , , ... tolerability of SB1518 in patients with CIMF and ... 1 part of the study will assess the safety profil...
(Date:12/1/2008)...he Prox1 gene is a two-way switch that, if turned ...ogrammed so that they lose their identity and beco...MPHIS, Tenn., Dec. 1 S... have discovered that a certain differentiated cel...requires the constant expression of a gene called ...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Cell Therapeutics Inc 28CTI 29 Prices 241 27 million 28euros 856 000 29 Offering of Common Stock through Societe Generale 2589 1Cell Therapeutics Inc 28CTI 29 Prices 241 27 million 28euros 856 000 29 Offering of Common Stock through Societe Generale 2589 2BioSpecifics Technologies Corp Announces Sale of Stock in Private Placement Offering 2587 1Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer 9536 1Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer 9536 2Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer 9536 3Rwandas Gishwati Forest selected as site for historic conservation project 1899 1Rwandas Gishwati Forest selected as site for historic conservation project 1899 2Rwandas Gishwati Forest selected as site for historic conservation project 1899 3
...RE)--Apr 19, 2007 - Amgen,(NASDAQ: AMGN) today ann...d, double-blind, placebo-controlled, multicenter P...00 previously untreated,patients with extensive-st...um-containing chemotherapy. The study demonstrated...f death (overall,survival Aranesp compared to plac...
...Apr 18, 2007 - Critical,Therapeutics, Inc. (Nasdaq...rch demonstrating a role in chronic inflammatory,a...otein (HMGB1), a,pro-inflammatory mediator and nuc... May 2007 issue of Nature Immunology. The,publicat...es that,can stimulate immune cells to produce pote...
Other Medicine Technology:Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 2Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 3Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 4Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 5Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 6Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 7Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 2Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 3Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 4Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 5
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs.
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay.
The Newmarket Laboratories RPR kits use carbon particles coated with a mixture of lipid antigens, which will combine with antibody present in patients serum or plasma. The particles are suspended in
For use as a quality assurance reagent in assays detecting IgG and IgM antibodies to Toxoplasma gondii (TOXO IgG and TOXO IgM), IgG and IgM antibodies to rubella virus (rubella IgG and rubella IgM),
Medicine Products: